705
+3.07%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kohjin Bio Co
Its shares trade on Tokyo Stock Exchange under the ticker 177A.T. It has been listed since 25 April 2024. In the fiscal year to 31 March 2025, it reported revenue of ¥5.21bn and net income of ¥794.8m. At that date it held total assets of ¥9.07bn and shareholders' equity of ¥5.78bn.
Kohjin Bio Co Ltd is a JP-based company operating in industry. The company is headquartered in Sakado-Shi, Saitama-Ken. The company went IPO on 2024-04-25. Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The firm operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 25 Apr 2024
- Employees
- 139
- Website
- kohjin-bio.jp ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kohjin Bio Co Ltd manufactures bacterial testing media in Japan with 139 employees.
- The Tissue Culture segment develops serum-free media for regenerative medicine research.
- The Microbiology segment provides pathogen testing media for clinical and food industries.
Weaknesses
- The company has only 139 employees and operates in a single city, Sakado-shi.
- Kohjin Bio Co Ltd's IPO was on 25 April 2024, a recent market entry.
- The Cell Processing segment is limited to facilities with Regenerative Medicine Safety Act permission.
Opportunities
- The Tissue Culture segment can expand into regenerative medicine markets in Japan.
- The Microbiology segment can grow in pharmaceutical and cosmetic quality testing sectors.
- The Cell Processing segment may increase contracts with medical institutions under the Regenerative Medicine Safety Act.
Threats
- The Microbiology segment faces competition from global diagnostic media providers.
- The Cell Processing segment is restricted by the Regenerative Medicine Safety Act regulations.
- The Tissue Culture segment depends on research funding for regenerative medicine.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.